摘要:
AIM To investigate the effects of Shuxuening Injection (Ginkgo biloba leaf extract) on serum lactic acid (Lac),soluble CD14-st (Presepsin) and nitric oxide synthase (NOS) levels in sepsis patients.METHODS One hundred and eight patients with sepsis treated by routine treatment in our hospital from Jan.2014 to Oct.2016 were randomly divided into two groups,control group and Shuxuening group (therapy group).Two weeks were one therapeutic course.Before the treatment (the onset of patients within 3 hours),at 6 hours and 5 days after the treatment,Lac and Presepsin levels were detected,and the changes of nitric oxide (NO),NOS,inducible nitric oxide synthase (iNOS) and sequential organ failure assessment (SOFA) score were observed.Incidence of major adverse cardiac events (MACE) and 28-day survival were recorded at the same time.RESULTS Before the treatment,there were no significant differences in SOFA score and the levels of Lac,Presepsin,NO,NOS and iNOS between the two groups (P > 0.05).Six hours after the treatment,the levels of Lac and Presepsin in the therapy group were lower than those in the control group (P < 0.05),both the two groups had lower levels of Lac and Presepsin than those before the treatment (P < 0.05);five days after the treatment,the levels of Lac and Presepsin in the two groups were lower than those at 6 hours after the treatment (P < 0.05),the levels of Lac and Presepsin in the therapy group were lower than those in the control group (P < 0.05).The SOFA score,NO,NOS and iNOS levels after the treatment in the therapy group were lower than those in the control group (P < 0.05).The levels of Lac and Presepsin in sepsis patients were positively correlated with SOFA score (r =0.245,0.261,P =0.011,0.006).The patients in the therapy group had lower incidence of MACE and 28-day mortality rate than those in the control group (P < 0.05).CONCLUSION The therapeutic effect of Shuxuening Injection combined with routine treatment on sepsis patients is superior to that of routine treatment,which can improve the prognosis of patients to a certain extent.%目的 考察舒血宁注射液(银杏叶提取物)对脓毒症患者血乳酸(Lac)、可溶性CD14亚型(Presepsin)、一氧化氮合酶(NOS)水平的影响.方法 我院2014年1月至2016年10月给予常规治疗的108例脓毒症患者随机分成对照组和舒血宁组(治疗组),2周为1个疗程.两组患者均在治疗前(患者发病3h内)及治疗后6h、5d,检测血Lac和Presepsin水平,观察一氧化氮(N0)、NOS、诱导型一氧化氮合酶(iNOS)和序贯器官功能衰竭评分(SOFA)变化,同时记录主要心脏不良事件(MACE)发生率和28 d生存情况.结果 治疗前两组Lac、Presepsin、NO、NOS、iNOS水平及SOFA评分比较无显著差异(P>0.05).治疗后6h,治疗组Lac和Presepsin水平均低于对照组(P<0.05),两组Lac和Presepsin水平均较治疗前降低(P<0.05).治疗后5d,两组Lac和Presepsin水平较治疗后6h降低(P<0.05),治疗组Lac和Presepsin水平低于对照组(P<0.05).治疗组治疗后SOFA评分、NO、NOS和iNOS水平低于对照组(P<0.05).脓毒症患者Lac和Presepsin水平与SOFA评分呈正相关(r=0.245、0.261,P=0.011、0.006).治疗组患者MACE发生率和28 d病死率低于对照组(P<0.05).结论 舒血宁注射液联合常规治疗对脓毒症患者的疗效优于常规治疗,在一定程度上可以改善患者预后.